Physician profile
Eric P Benson
NPI 1639272644
$19,156.51
in general payments reported to CMS, 2019-2025
55 companies · $2,949 in 2025
The $2,949 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,898 · 2020: $1,970 · 2021: $2,708 · 2022: $2,508 · 2023: $2,941 · 2024: $3,183 · 2025: $2,949.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,061 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,061.24 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,777.09 | 2019-2025 | Trelegy Ellipta, Nucala, Shingrix |
| Amgen INC. | $1,772.74 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $1,404.99 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Lilly USA, LLC | $1,167.88 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $1,084.59 | 2019-2025 | Farxiga, Airsupra |
| Teva Pharmaceuticals USA, INC. | $929.04 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $922.17 | 2019-2024 | Xarelto |
| Pfizer INC. | $846.07 | 2019-2025 | |
| Novo Nordisk INC | $760.13 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $719.86 | 2021-2025 | |
| Daiichi Sankyo INC. | $630.75 | 2019 | |
| Corcept Therapeutics | $602.80 | 2021-2025 | Korlym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $549.38 | 2022-2024 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $464.38 | 2019-2025 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $456.26 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $382.84 | 2022-2025 | Vyepti, Rexulti |
| Exact Sciences Corporation | $320.28 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $268.48 | 2019-2021 | |
| Grifols USA, LLC | $227.68 | 2019-2023 | Prolastin-C Liquid |
| Sanofi-Aventis U.S. LLC | $199.81 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $188.35 | 2021-2025 | Xtampza, Belbuca |
| Abbott Laboratories | $186.72 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $184.16 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $163.84 | 2019-2025 | |
| Antares Pharma, INC. | $157.80 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Merck Sharp & Dohme LLC | $152.72 | 2019-2024 | Dificid |
| Astellas Pharma US INC | $147.25 | 2019-2021 | |
| Esperion Therapeutics, INC. | $146.66 | 2020-2021 | |
| Eisai INC. | $129.27 | 2020-2022 | |
| Allergan, INC. | $129.14 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $106.78 | 2022 | |
| Radius Health, INC. | $106.27 | 2019-2024 | Tymlos |
| Biohaven Pharmaceuticals, INC. | $102.35 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $92.27 | 2023-2024 | Glassia, Trintellix |
| Mylan Specialty L.P. | $84.29 | 2023-2024 | Yupelri |
| Sanofi Pasteur INC. | $68.47 | 2019-2021 | |
| Boston Scientific Corporation | $58.87 | 2021-2025 | Watchman Flx |
| Sumitomo Pharma America, INC. | $52.59 | 2025 | Gemtesa |
| Upsher-Smith Laboratories LLC | $50.84 | 2020-2021 | |
| Recordati_rare_diseases_inc. | $42.21 | 2025 | Isturisa |
| Viatris Specialty LLC | $39.74 | 2025 | Yupelri |
| Dexcom, INC. | $24.65 | 2025 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $24.49 | 2019-2020 | |
| Biogen, INC. | $24.05 | 2021 | |
| Horizon Therapeutics Plc | $22.21 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.57 | 2021 | |
| Nevro Corp. | $21.44 | 2021 | |
| Baxter Healthcare | $20.69 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Phathom Pharmaceuticals, INC. | $20.16 | 2024 | Voquezna |
| Edwards Lifesciences Corporation | $19.51 | 2025 | Sapien 3 Ultra Resilia |
| Xeris Pharmaceuticals, INC. | $19.06 | 2025 | Recorlev |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.83 | 2024 | Rexulti |
| Almatica Pharma LLC | $15.40 | 2021 | |
| Therapeuticsmd, INC. | $14.05 | 2019 | |
| Genentech USA, INC. | $13.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Benson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.